Gene–disease relationship
ClinGen classifies ASH1L-related syndromic neurodevelopmental disorder as definitive, with autosomal dominant inheritance.
ASH1L CLINICIAN ORIENTATION
Know what is established. Evaluate the person in front of you.
A concise orientation to the ASH1L gene–disease relationship, published human phenotype, molecular and clinical limits, first-encounter priorities, and systematic assessment of new change.
CLINICAL ORIENTATION · FIVE ESSENTIALS
The diagnosis is real. Its individual prediction is limited.
Use established gene-level evidence to frame the diagnosis, then return to the exact molecular report, the published evidence for the question, and the person’s own baseline.
REFERENCE IDENTITY
ASH1L
ASH1 like histone lysine methyltransferase
- HGNC
- 19088
- NCBI Gene
- 55870
- Locus
- 1q22
- Inheritance
- Autosomal dominant
- ClinGen validity
- Definitive
- Haploinsufficiency
- Sufficient evidence
Established mechanism
Haploinsufficiency has sufficient evidence. Loss-of-function is an established disease mechanism; variant interpretation still belongs at the exact allele and report level.
Human phenotype
Published series support a heterogeneous neurodevelopmental disorder. Development, language, cognition, behavior, motor function, sleep, seizures, feeding, growth, and other findings vary across people and studies.
Allele-specific interpretation
Missense, splice, CNV, in-frame, and complex findings are not automatically equivalent to truncating loss of function. Preserve transcript, classification, inheritance, method, and additional findings.
What is not yet established
No validated ASH1L-specific biomarker, disease-modifying therapy, or universal surveillance panel is established. Evaluate and manage the presenting concern using ordinary clinical standards and individualized supports.
FIRST CLINICAL ENCOUNTER
Five steps that make the visit more useful.
These steps are deliberately concern-directed. They do not imply that every person needs every specialty, test, or surveillance pathway.
- 01Verify the molecular record
Use the complete signed report: transcript, cDNA and protein lines, classification, inheritance, method, limitations, parental testing, and additional findings.
- 02Define the person’s baseline
Record communication, mobility, daily function, sleep, feeding, safety, successful supports, and the family’s current priorities.
- 03Name the clinical question
Separate longstanding phenotype from a new, episodic, progressive, or context-linked change.
- 04Evaluate by concern
Use developmentally and communication-appropriate standard care. Avoid both a universal ASH1L checklist and diagnostic overshadowing.
- 05Close the loop
State what is known, what remains uncertain, what the next observation or test should answer, and who will communicate follow-up.
CORE CLINICAL PRINCIPLE
“Behavior” describes what was observed. It does not establish why it happened.
A functional or behavioral interpretation may be appropriate, but it should follow a proportionate assessment of pain, illness, neurologic events, sleep, medication effects, communication, sensory demands, and psychosocial context.
URGENT CHANGE
Use ordinary clinical urgency thresholds.
New prolonged unresponsiveness, convulsive activity, focal weakness, breathing difficulty, severe dehydration, serious injury, fever with toxic appearance, or abrupt loss of function requires urgent evaluation according to the clinical context. An ASH1L diagnosis should not delay standard emergency assessment.
SYSTEMATIC CLINICAL REVIEW
Eight areas to review before a change is reduced to behavior.
These domains can coexist. The list organizes history and examination; it does not replace clinical judgment or imply that ASH1L caused the event.
Pain or physical illness
Dental and ENT pain, reflux, constipation, urinary symptoms, injury, musculoskeletal pain, infection, and other sources that may be difficult to localize or communicate.
Neurologic change
Seizures or nonepileptic spells, altered awareness, headache, new weakness or asymmetry, movement change, gait deterioration, regression, and post-event recovery.
Sleep and breathing
Sleep loss, fragmentation, sleep-disordered breathing, nocturnal events, circadian disruption, daytime somnolence, and the timing of symptoms around sleep.
GI, intake, and hydration
Bowel burden, feeding or swallowing change, nausea, reflux, dehydration, weight change, food refusal, and whether symptoms improve after eating, drinking, or toileting.
Medication or procedure effects
New medication, dose or formulation change, interaction, withdrawal, paradoxical activation, sedation, anesthesia, pain control, and delayed return to baseline.
Hormonal, metabolic, or autonomic state
Menstrual or pubertal timing, temperature, sweating, pallor or flushing, heart rate, glucose or electrolyte concerns, and reproducible physiologic context.
Sensory and environmental demands
Noise, light, transitions, task demands, communication mismatch, fatigue, unfamiliar settings, and whether reduced demands change the event without explaining its cause.
Mental health and psychosocial context
Anxiety, mood, trauma, grief, stress, and environmental change—considered alongside, not instead of, physical and neurologic assessment.
Example · interpret a normal test narrowlyESR and CRP do not close the differential
LAB INTERPRETATION
A normal study answers only the question it captured.
ESR and CRP are nonspecific acute-phase markers from one sampling time. They do not exclude seizures, sleep-disordered breathing, bowel or dental disease, arrhythmia or syncope, endocrine or metabolic disease, localized tissue pathology, or every immune disorder.
Follow the observed phenotype with the test that can answer it. Pediatric inflammatory-bowel cohorts also document active disease with both markers in range.
AT THE VISIT
Five questions that make the history clinically useful.
Family observations are most useful when they are converted into timing, function, context, co-occurring signs, and recovery—not dismissed or asked to carry a diagnosis.
What changed?
Describe the observable event before naming it: awareness, movement, color, breathing, vocalization, posture, gait, communication, pain behavior, or loss of a previously reliable function.
When and for how long?
Record onset, frequency, duration, clustering, time of day, relation to sleep or meals, and whether the pattern is progressive, episodic, or a single event.
What is the baseline?
Define what the person could access reliably before the change and whether recovery is complete, delayed, or establishing a new baseline.
What travels with it?
Capture illness, bowel state, intake, medication, hormonal timing, pain, vital-sign change, sensory context, procedure, and objective neurologic features.
Was the event captured?
Interpret EEG, imaging, laboratory, sleep, cardiac, or other testing in relation to acquisition quality and whether the relevant state or event actually occurred during the study.
ASH1L-SPECIFIC ORIENTATION
Use the connected group to sharpen questions—not to shortcut the differential.
SPELLS & SEIZURES
Separate event classes.
Reported seizures, EEG-only findings, unresolved staring or spells, and documented nonepileptic events are distinct. Ask about awareness, motor signs, duration, triggers, recovery, and whether a representative event was captured.
Review seizure phenotypes →STATE & RECOVERY
Timing and recovery can reveal important patterns.
Sleep, illness, constipation, intake, medication, procedures, hormonal timing, and sensory demands may modify access to communication, movement, and regulation. Record recovery as carefully as onset.
Review state measurement →FUNCTION
Document when a known skill becomes difficult to use.
A skill may still exist but become intermittently inaccessible. Define what changed across home, school, therapy, and clinic, and whether the same supports restore function consistently.
Open Development & Memory →EXTERNAL CLINICAL STANDARD
Physical health, pain, medication, and family knowledge belong in the assessment.
NICE guidance for people with learning disabilities and behavior that challenges recommends reviewing how emerging behavior may relate to physical health problems, medication effects, and pain, and involving people who know the person well.
Open NICE NG11 recommendations ↗CORE ASH1L REFERENCES
Start with the source that can answer the question.
The full Evidence Library keeps published findings, model-system results, and their limits together.
Open filtered human evidence